Profund Advisors LLC Acquires 1,024 Shares of Eli Lilly and Company $LLY

Profund Advisors LLC lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 8.7% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 12,758 shares of the company’s stock after purchasing an additional 1,024 shares during the quarter. Profund Advisors LLC’s holdings in Eli Lilly and Company were worth $9,945,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in LLY. Brighton Jones LLC lifted its stake in Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after purchasing an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC raised its stake in Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after buying an additional 40 shares during the period. Covestor Ltd lifted its position in Eli Lilly and Company by 24.9% in the 1st quarter. Covestor Ltd now owns 426 shares of the company’s stock valued at $352,000 after acquiring an additional 85 shares in the last quarter. Kaufman Rossin Wealth LLC purchased a new stake in Eli Lilly and Company in the 1st quarter valued at $242,000. Finally, Opes Wealth Management LLC grew its holdings in shares of Eli Lilly and Company by 6.6% in the first quarter. Opes Wealth Management LLC now owns 337 shares of the company’s stock valued at $278,000 after acquiring an additional 21 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Down 1.5%

Shares of Eli Lilly and Company stock opened at $923.35 on Monday. The company’s 50 day moving average price is $799.97 and its 200-day moving average price is $775.01. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $955.46. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The stock has a market capitalization of $872.92 billion, a price-to-earnings ratio of 60.35, a P/E/G ratio of 1.21 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The firm had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company’s revenue for the quarter was up 53.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be given a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Guggenheim reaffirmed a “buy” rating and issued a $948.00 price objective on shares of Eli Lilly and Company in a report on Thursday, October 16th. BMO Capital Markets boosted their target price on shares of Eli Lilly and Company from $930.00 to $1,100.00 and gave the company an “outperform” rating in a report on Thursday. DZ Bank upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. Finally, JPMorgan Chase & Co. dropped their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a report on Tuesday, September 16th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $960.88.

Insider Activity at Eli Lilly and Company

In other news, Director Gabrielle Sulzberger bought 117 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the acquisition, the director owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Daniel Skovronsky bought 1,000 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average cost of $634.40 per share, with a total value of $634,400.00. Following the transaction, the executive vice president directly owned 137,660 shares in the company, valued at approximately $87,331,504. This represents a 0.73% increase in their position. The SEC filing for this purchase provides additional information. Over the last quarter, insiders bought 4,314 shares of company stock worth $2,766,929. 0.13% of the stock is currently owned by company insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.